Can We Increase the Resection Rate by Minimally Invasive Approach? Experience from 100 Minimally Invasive Esophagectomies
Table 1
Patient characteristics.
Fit for any approach n=90
Fit for MIE only n=10
No surgery n=19
P value: Any approach – MIE only
P value: Any approach – No surgery
P value: MIE only – No Surgery
Age yrs (median, IQR)
68 (59-72)
70 (59-83)
73 (61-86)
0.172
0.014
0.359
BMI kg/m2 (median, IQR)
25.0 (22.5-28.3)
28.9 (22.3-35.7)
20.8 (19.6-no data)
0.111
0.065
0.116
Male, n (%)
68 (75.6)
7 (70.0)
12 (63.2)
0.700
0.266
0.713
WHO performance status, n (%)
<0.001
<0.001
0.306
Grade 0
60 (66.7)
2 (20.0)
1 (5.3)
Grade I
29 (32.2)
6 (60.0)
10 (52.6)
Grade II
1 (1.1)
2 (20.0)
8 (42.1)
Charlson comorbidity index (%)
0
47 (52.2)
5 (50.0)
9 (47.4)
0.727
0.923
0.761
1
25 (27.8)
2 (20.0)
6 (31.6)
≥2
18 (20.0)
3 (30.0)
4 (21.1)
Stair climbing
0.004
<0.001
0.417
4 or more
70 (77.8)
5 (50.0)
7 (36.8)
Less than 4
20 (22.2)
5 (50.0)
12 (63.2)
FEV1% (median, IQR)
85 (77-99)
95 (76-104)
71 (55-99)
0.493
0.173
0.133
Histology, n (%)
0.739
0.003
0.153
Adenocarcinoma
72 (80.0)
7 (70.9)
8 (42.1)
Squamous cell cancer
18 (20.0)
3 (30.0)
11 (57.9)
Tumor location
0.444
0.026
0.118
Upper or middle
6 (6.7)
-
4 (21.1)
Distal or junction
84 (93.3)
10 (100)
15 (78.9)
Sievert
0.471
0.295
0.072
I
39 (43.3)
3 (30.0)
10 (52.6)
II
42 (46.7)
7 (70.0)
5 (26.3)
III
3 (3.3)
-
-
Oncological therapy
<0.001
<0.001
0.015
None
16 (17.8)
5 (50.0)
1 (5.3)
Neoadjuvant chemotherapy
30 (33.3)
1 (10.0)
3 (15.8)
Neoadjuvant chemoradiotherapy
44 (48.9)
1 (10.0)
4 (21.1)
Other oncological treatments
-
3 (30.0)1
11 (57.9)2
Surgical approach
0.885
-
-
McKeown
10 (11.1)
1 (10.0)
Ivor Lewis
78 (86.7)
9 (90.0)
Colon interposition
2 (2.2)
-
Clinical Stage, n (%)
<0.001
0.867
0.049
I
17 (17.8)
2 (20.0)
3 (15.8)
II
37 (41.1)
4 (40.0)
7 (36.8)
III
36 (40.0)
2 (20.0)
9 (47.4)
IV
-
2 (20.0)
-
Gradus
0.273
0.018
0.483
1
11 (12.2)
3 (30.0)
7 (36.8)
2
42 (46.7)
3 (30.0)
8 (42.1)
3
16 (17.8)
3 (30.0)
4 (21.1)
Pathological Stage, n (%)
0.777
-
-
0 (Complete response)
19 (21.1)
1 (10.0)
I
22 (24.4)
3 (30.0)
II
25 (27.8)
3 (30.0)
III
24 (26.7)
3 (30.0)
IV
-
-
two patients with prior oncological treatment due to synchronous liver metastases and one with persistent disease after definitive chemoradiotherapy. Table 4. Including 7 patients with palliative radiotherapy and 4 patients with definitive chemoradiotherapy.
